TCL1 Monoclonal Antibody (eBio1-21 (1-21)), eBioscience™, Invitrogen™

Description

• The eBio1-21 antibody reacts with human T cell leukemia/lymphoma 1 (TCL1), a 14 kDa proto-oncogene product with a suggested role in intracellular regulation of T cell signalling
• TCL1 was identified as the oncogene located at the 14q32.1 chromosome breakpoint region in T-cell prolymphocytic leukemia (T-PLL)
• In T-PLL, TCL1 is overexpressed as a result of an inversion or a reciprocal translocation, by juxtaposition to the T-cell receptor promoter/enhancer elements
• TCL1 binds to the pleckstrin homology domain of Akt (protein kinase B) family proteins, which facilitates Akt dimerization and activity
• By increasing Akt activity TCL1 may enhance the serine/threonine phosphorylation of major Akt signaling substrates, such as Ikk complex, mTOR, BAD, p70S6 kinase, FOXO transcription factors, and GSK3beta
• These substrates regulate cellular differentiation, growth, survival, and metabolism
• Besides its tumorigenic role in T-PLL, TCL1 is normally expressed in the CD3-CD4-CD8- subset of thymic precursors in the T cell lineage, the plasmacytoid subset of dendritic cells, stimulated (not resting) mature T cells, and B cells up to the germinal center stage of maturation
• TCL1 is inappropriately expressed by chromosome rearrangements that lead to pre-malignant clonal T cell expansions and mature T cell tumors
• TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia (CLL)
• Overexpression of the TCL1 gene in humans has been implicated in the development of mature T cell leukemia, in which chromosomal rearrangements bring the TCL1 gene in close proximity to the T-cell antigen receptor (TCR)-alpha or TCR-beta regulatory elements (summarized by Virgilio et al., 1998)
• In normal T cells TCL1 is expressed in CD4-/CD8- cells, but not in cells at later stages of differentiation
• TCL1 functions as a coactivator of the cell survival kinase AKT (Laine et al., 2000).